Compare J.B.Chemicals with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs DISHMAN PHARMA - Comparison Results

J.B.CHEMICALS     Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS DISHMAN PHARMA J.B.CHEMICALS/
DISHMAN PHARMA
 
P/E (TTM) x 16.5 25.1 65.8% View Chart
P/BV x 3.0 3.3 88.7% View Chart
Dividend Yield % 0.4 0.7 59.6%  

Financials

 J.B.CHEMICALS   DISHMAN PHARMA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-18
DISHMAN PHARMA
Mar-16
J.B.CHEMICALS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs363374 97.0%   
Low Rs255129 197.8%   
Sales per share (Unadj.) Rs169.1197.8 85.5%  
Earnings per share (Unadj.) Rs16.621.2 78.3%  
Cash flow per share (Unadj.) Rs23.434.7 67.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.60.8 81.4%  
Book value per share (Unadj.) Rs172.5179.9 95.9%  
Shares outstanding (eoy) m83.5780.69 103.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.81.3 143.6%   
Avg P/E ratio x18.611.9 156.9%  
P/CF ratio (eoy) x13.27.2 182.1%  
Price / Book Value ratio x1.81.4 128.1%  
Dividend payout %12.09.4 127.8%   
Avg Mkt Cap Rs m25,82720,306 127.2%   
No. of employees `0003.80.8 455.0%   
Total wages/salary Rs m2,5115,355 46.9%   
Avg. sales/employee Rs Th3,747.419,252.7 19.5%   
Avg. wages/employee Rs Th665.76,459.5 10.3%   
Avg. net profit/employee Rs Th367.82,064.1 17.8%   
INCOME DATA
Net Sales Rs m14,13515,961 88.6%  
Other income Rs m366265 137.8%   
Total revenues Rs m14,50116,226 89.4%   
Gross profit Rs m2,1784,103 53.1%  
Depreciation Rs m5701,091 52.2%   
Interest Rs m35944 3.7%   
Profit before tax Rs m1,9402,334 83.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m552624 88.6%   
Profit after tax Rs m1,3871,711 81.1%  
Gross profit margin %15.425.7 59.9%  
Effective tax rate %28.526.7 106.6%   
Net profit margin %9.810.7 91.5%  
BALANCE SHEET DATA
Current assets Rs m10,47011,018 95.0%   
Current liabilities Rs m2,7499,517 28.9%   
Net working cap to sales %54.69.4 580.9%  
Current ratio x3.81.2 329.0%  
Inventory Days Days55110 50.0%  
Debtors Days Days7835 222.9%  
Net fixed assets Rs m5,81116,304 35.6%   
Share capital Rs m167161 103.5%   
"Free" reserves Rs m14,24812,907 110.4%   
Net worth Rs m14,41614,516 99.3%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m17,64929,805 59.2%  
Interest coverage x56.63.5 1,629.9%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.5 149.6%   
Return on assets %8.18.9 90.4%  
Return on equity %9.611.8 81.6%  
Return on capital %13.717.5 78.1%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m6,1644,952 124.5%   
Fx outflow Rs m1,334697 191.5%   
Net fx Rs m4,8294,255 113.5%   
CASH FLOW
From Operations Rs m1,2312,786 44.2%  
From Investments Rs m-208-1,529 13.6%  
From Financial Activity Rs m-595-941 63.2%  
Net Cashflow Rs m427316 135.0%  

Share Holding

Indian Promoters % 55.4 61.4 90.2%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 3.7 91.6%  
FIIs % 3.9 12.7 30.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 22.1 167.4%  
Shareholders   30,437 46,261 65.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare J.B.CHEMICALS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views on News

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Apr 1, 2020 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 8-QTR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS